Executive Summary The use of Precision Medicine (PM) is increasing across Asia at a pace that outstrips the capacity of existing Health Technology Assessment (HTA) and reimbursement systems to respond. The “Workshop on Paying for Precision Medicine Sustainably in Asia: Reimbursement Barriers, Ena

22nd May 2014Dr.Yot gave a Skype  interviewed to Richard Smith,Professor of Health System Economics & Dean of Faculty of Public Health & Policy, London School of Hygiene & Tropical Medicine for making the Health Economics and Health Technology Assessment (HTA) VideoHere’re some behind th

President Obama’s health care law is putting new strains on some of the nation’s most hard-pressed hospitals, by cutting aid they use to pay for emergency care for illegal immigrants, which they have long been required to provide.The federal government has been spending $20 billion annually to reimb

Epidemiological modelling is an important tool to help public health planners understand potential disease outcomes in the population. The recent visibility of models and their perceived influence in the decision-making processes surrounding the response to the COVID-19 pandemic has led to a great d

In Thailand, the prevalence of chronic kidney disease (CKD) is 17.5% of the population (Ingsathit et al., 2010). According to Thailand’s National Health Security Office (2021), in each year, this public health agency spends approximately 10,000 million Baht in renal dialysis and 1,000 million Baht f

Background: Telemedicine has transformed health care delivery, offering improved access, efficiency, and potentially cost-effectiveness. However, wide-scale implementation is challenged due to multiple factors. Among these, reimbursements were reported to influence the scalability and sustainabilit

Benjarin Santatiwongchai1, Varit Chantarastapornchit1*, Thomas Wilkinson2, Kittiphong Thiboonboon1, Waranya Rattanavipapong1, Damian G Walker3, Kalipso Chalkidou2, Yot Teerawattananon1 1 Health Intervention and Technology Assessment Program, Nonthaburi, Thailand, 2 NICE International,National Insti

“Health donors, policymakers, and practitioners continuously make life-and-death decisions about which type of patients receive what interventions, when, and at what cost. These decisions—as consequential as they are— often result from ad hoc, nontransparent processes driven more by inertia and inte

The Health Technology Assessment (HTA), which is a crucial tool for setting health intervention priorities, has been rapidly developing in Asia-Pacific, but is still not fully employed by many countries in policy decision making. Although HTA institutions and networks have been operating successfully in OECD countries and a few of the middle-income

Rapeepong Suphanchaimat1,2 Angkana Sommanustweechai1 , Chiraporn Khitdee1 , Chompoonut Thaichinda1 , Kanang Kantamaturapoj3 , Pattara Leelahavarong4 , Pensom Jumriangrit1 , Thitikorn Topothai1 , Thunthita Wisaijohn1 Weerasak Putthasri1 1International Health Policy Program (IHPP), Ministry of Publi